Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AdAlta Ltd. ( (AU:1AD) ) has provided an announcement.
AdAlta has signed a Memorandum of Understanding with Oribiotech and Cell Therapies to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and the wider Asia-Pacific region. The deal will see IRO used across AdAlta’s cellular immunotherapy pipeline and at Cell Therapies’ facilities for process development and clinical manufacturing.
The IRO platform is designed to tackle major CAR-T manufacturing bottlenecks by automating key steps, targeting 10–50 times higher throughput, faster production and potential cost savings of 30–50%. By improving scalability and lowering costs, the collaboration is intended to broaden patient access to cell therapies, strengthen AdAlta’s globalisation strategy and reinforce Cell Therapies’ position as a leading regional contract manufacturer in advanced cell therapies.
More about AdAlta Ltd.
AdAlta Limited is an Australian biotechnology company developing next-generation cellular immunotherapies, including CAR-T therapies, with a focus on solid tumour cancers such as mesothelioma. The company aims to build an “East to West” strategy, positioning itself as a developer of scalable, cost-effective cell therapies for global markets, particularly across the Asia-Pacific region.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.2M
Learn more about 1AD stock on TipRanks’ Stock Analysis page.